Prior treatment with lucitanib

Active second malignancy

Active central nervous system brain metastases

Pre-existing duodenal stent or any gastrointestinal disorder

Known history of HIV or AIDs; positive result of hepatitis B or C viruses

Evidence of interstitial lung disease, active pneumonitis, myocarditis, or history of myocarditis

Active, known or suspected autoimmune disease (eg, autoimmune hepatitis)

Condition requiring systemic treatment with corticosteroids or other immune suppressive medications

Unstable or uncontrolled hypertension (BP ≥ 140/90 mmHg)

Prior treatment with a VEGFR-tyrosine kinase inhibitor (Phase 2)

A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor